(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 September 2013 (19.09.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/135892 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 47/24* (2006.01)
A61K 47/18 (2006.01) *A61K 9/127* (2006.01)
A61K 47/22 (2006.01)

(21) International Application Number:
PCT/EP2013/055471

(22) International Filing Date:
15 March 2013 (15.03.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1204632.2 16 March 2012 (16.03.2012) GB

(71) Applicant: **THE QUEEN'S UNIVERSITY OF BELFAST** [GB/GB]; University Road, Belfast BT71NN (GB).

(72) Inventors: **KETT, Victoria**; School of Pharmacy, The Queen's University of Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast Antrim BT97BL (GB). **YUSUF, Helmy**; School of Pharmacy, The Queen's University of Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast Antrim BT97BL (GB). **MCCARTHY, Helen**; School of Pharmacy, The Queen's Unversity of Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast Antrim BT97BL (GB). **CHEN, Kun Hung**; No. 320, Changsing St., Siangshan Dist., 30059 Hsinchu City (TW).

(74) Agent: **HALLY, Anna-Louise**; FRKelly, 4 Mount Charles, Belfast Antrim BT71NZ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

[Continued on next page]

(54) Title: LIPOSOMAL DELIVERY SYSTEM




Figure 1

(57) Abstract: The present invention is directed to a liposomal delivery system comprising defined lipid components, including dimethyldioctadecylammonium and other lipid components and a stabilizing agent, which may be used in the delivery of bioactive agents to a subject in need thereof. The liposomal delivery system of the invention provide improvements in terms of delivery and stability. Ideally, the liposomal delivery system is used as a vaccine or drug/medicament delivery system although other bioactive agents may be delivered.

WO 2013/135892 A1

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*